Ryan Kauffman, MD
Otolaryngology · Marietta, GANPI 1881873271
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.0% of the total across 186 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations.
Across 186 payments — averaging $25.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$989
- Optinose US, Inc.$646
- GSK$428
- Regeneron Healthcare Solutions, Inc.$383
- Intersect ENT, Inc.$363
- Medtronic$308
- plus $2K from 23 others
What the payments were for
- Consulting fees$1002%
- Food & beverage$4,53994%
- Education$1914%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 35 | $989 |
| Optinose US, Inc. | 27 | $646 |
| GSK | 17 | $428 |
| Regeneron Healthcare Solutions, Inc. | 11 | $383 |
| Intersect ENT, Inc. | 11 | $363 |
| Medtronic | 7 | $308 |
| Acclarent, Inc | 15 | $200 |
| Hikma Pharmaceuticals USA | 10 | $183 |
| Aerin Medical Inc. | 8 | $169 |
| Integra Lifesciences Corporation | 1 | $150 |
| Stryker | 7 | $149 |
| Kaleo, Inc. | 9 | $148 |
| Sanofi-aventis U.S. LLC | 1 | $99 |
| Alk-abello, Inc | 4 | $84 |
| Itamar Medical Inc | 1 | $78 |
| Amgen | 3 | $66 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $58 |
| Neurent Medical Limited | 2 | $51 |
| Fortovia Therapeutics, Inc. | 3 | $48 |
| Merck | 2 | $43 |
| Paratek Pharmaceuticals, Inc. | 1 | $27 |
| Johnson & Johnson | 2 | $27 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| AstraZeneca | 1 | $25 |
| Hologic Sales And Service, LLC | 1 | $22 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $14 |
| Olympus America Inc. | 1 | $13 |
| Cochlear Americas | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$369
- PROPEL$206
- Acclarent Aera$150
- Inspira Air$150
- RELIEVA SPINPLUS NAV$150
- TruDi Probe$150
- NUCALA$111
- Xhance$109
How this compares
$4,830 in reported general payments places this provider in the 85th percentile of 308 otolaryngology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 15 | $55,404 |
| Dupixent SyringeDupilumab | 13 | $46,109 |
| Ipratropium Bromide | 482 | $16,439 |
| Azelastine Hcl | 469 | $12,660 |
| Epinephrine | 34 | $6,886 |
| Mometasone Furoate | 152 | $4,809 |
| Ciprofloxacin-DexamethasoneCiprofloxacin Hcl/Dexameth | 39 | $4,413 |
| Gabapentin | 328 | $3,386 |
| Montelukast Sodium | 379 | $3,332 |
| Pantoprazole Sodium | 250 | $2,084 |
| Fluticasone Propionate | 121 | $1,657 |
| Famotidine | 120 | $1,205 |
| Triamcinolone Acetonide | 38 | $917 |
| Celecoxib | 39 | $739 |
| Levothyroxine Sodium | 64 | $613 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Hikma Pharmaceuticals USAEpinephrine | $183 | $6,88634 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 308 otolaryngology providers in Georgia.
Other otolaryngology in Marietta
- Lawrence WeissMarietta$9K
- Drew LocandroMarietta$6K
- Khaled KashlanMarietta$4K
- Hannan QureshiMarietta$4K
- Dozier HoodFayetteville$347K
- Christopher MelroySavannah$298K
- Karen HoffmannAtlanta$223K
- Jose StolovitzkyAtlanta$81K
- Jonathan LindmanEvans$55K
- Gregory PostmaAugusta$37K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.